Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MPO | P05164 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | IL1RN | P18510 | 3/20 | 0.56 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.56 |
| ▸ | ECE1 | P42892 | 4/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30800609 | 0.92 | KMT2A (0.66) | ACEMEN1KMT2AHCRTR1KDM4E | |
| SCHEMBL20829913 | 0.92 | KMT2A (0.66) | ACEMEN1KMT2AHCRTR1KDM4E | |
| SCHEMBL11660007 | 0.90 | IL1RN (0.61) | ACEMEN1KMT2AHCRTR1KDM4E | |
| Hydrochloric Acid SCHEMBL11662208 | 0.89 | IL1RN (0.61) | ACEMEN1KMT2AHCRTR1KDM4E | |
| SCHEMBL11664273 | 0.88 | IL1RN (0.67) | IL1RNERAP2ECE1 | |
| SCHEMBL20829962 | 0.88 | ERAP2 (0.61) | MEN1KMT2AHCRTR1KDM4ELMNA | |
| SCHEMBL29350923 | 0.88 | IL1RN (0.67) | IL1RNERAP2ECE1 | |
| SCHEMBL30374944 | 0.88 | ERAP2 (0.61) | MEN1KMT2AHCRTR1KDM4ELMNA | |
| SCHEMBL26817747 | 0.88 | ACE (0.69) | ACEMEN1KMT2AHCRTR1KDM4E | |
| SCHEMBL31184558 | 0.88 | ACE (0.69) | ACEMEN1KMT2AKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570688-B2 | Activated cysteine-directed polypeptide ligation technique | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2026-03-10 | — | — | US | disclosed |
| US-20230002442-A1 | AN ACTIVATED CYSTEINE-DIRECTED POLYPEPTIDE LIGATION TECHNIQUE | THE TEXAS A&M UNIVERSITY SYSTEM | 2023-01-05 | — | — | US | disclosed |
| EP-4085139-A1 | AN ACTIVATED CYSTEINE-DIRECTED POLYPEPTIDE LIGATION TECHNIQUE | The Texas A&M University System (US) | 2022-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570688-B2 | Activated cysteine-directed polypeptide ligation technique | PTMS, LNPEP, ANPEP | ACE 2192/4885MEN1 3564/4885KMT2A 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.